Mary DeRome, Senior Director of Medical Communications and Education at the Multiple Myeloma Research Foundation, gets answers to frequently asked questions on bispecific antibodies from Jesus Berdeja, MD (Director of Multiple Myeloma Research, Tennessee Oncology), and Melissa Alsina, MD (Head, Myeloma BMT-CI Program, H. Lee Moffitt Cancer Center and Research Institute).

These experts provide answers to questions about the latest on bispecific antibody therapies. Topics include…

Bispecific antibody therapy – general
Treatment sequencing
Treatment toxicity
What’s next with bispecifics?

This session is supported by AbbVie, Genentech, Janssen, Pfizer, Regeneron.

If you have questions, call our MMRF Patient Navigation Center at 1-888-841- 6673.

Your feedback is important. Please complete a brief survey: http://tinyurl.com/LSBsAbs